Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Moreau, Philippe; Masszi, Tamás; Grząśko, Norbert; J. Bahlis, Nizar; Hansson, Markus; Pour, Luděk; Sandhu, Irwindeep; Ganly, Peter; W. Baker, Bartrum; Jackson, Sharon; Stoppa, Anne-Marie; R. Simpson, David; Gimsing, Peter; Palumbo, Antonio; Garderet, Laurent; Cavo, Michèle; Kumar, Shaji; Touzeau, Cyrille; K. Buadi, Francis; P. Laubach, Jacob; Berg, Deborah; Lin, Jianchang; Di Bacco, Alessandra; Hui, Ai-Min; van de Velde, Helgi; G. Richardson, Paul

doi:10.1056/nejmoa1516282

Public

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Published in New England Journal of Medicine • Apr 27, 2016

Authors:

Philippe Moreau

Tamás Masszi

Norbert Grząśko

Abstract

BACKGROUND: Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to...

Subject

Lenalidomide

Ixazomib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!